Doç. Dr. Halil Genç

- Yüksekova/Hakkari Dağ Komando Tugayı- Dağlıca İç Güvenlik Taburu
- Kıbrıs Türk Barış Kuvvetleri
- Cumhurbaşkanlığı Muhafız Alayı- Ankara
- Kara Kuvvetleri Komutanlığı Karargah Reviri Dahiliye Uzmanı
- Gülhane Tıp Fakültesi Hastanesi - Ankara
- İzmir Asker Hastanesi
- Özel Batıgöz Cerrahi Tıp Merkezi/Balçova İzmir

1. Genc H, Dogru T, Tapan S ve ark. Soluble CD40 ligand, soluble P-selectin and von Willebrand factor levels in subjects with prediabetes: The impact of metabolic syndrome. Clin Biochem. 2012 Jan;45(1-2):92-5.

2. Genc H, Dogru T, Tapan S ve ark. Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol. 2011;46(11):1355-61.

3. Sonmez A, Haymana C, Tapan S, Safer U, Celebi G, Ozturk O, Genc H, ve ark. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. Endocrine. 2010;37(3):455-9.

4. Kilciler G, Genc H, Tapan S, ve ark. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci. 2010;115(4):253-9.

5. Tapan S, Dogru T, Kara M, Ercin CN, Kilciler G, Genc H, ve ark. Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2010;70(6):399-403.

6. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H ve ark. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179-83.

7. Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H, ve ark. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2009;204(1):222-

8. Erdem G, Genç H, Tapan S, ve ark. Circulating von Willebrand factor levels in patients with prediabetes. Turkish J Med Sci 2008;28(6):822-27.

9. Dogru T, Genc H, Tasci I, ve ark. Platelet aggregation is not enhanced in patients with prediabetes. Ups J Med Sci. 2007;112(3):338-46.

10. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H ve ark. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76(1):24-9.

11. Tasci I, Dogru T, Sonmez A, Genc H ve ark. Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose. Mediators Inflamm. 2006;2006(5):32508.

12. Dogru T, Tasci I, Sonmez A, Genc H, ve ark. The plasma levels of soluble P-selectin in subjects with prediabetes. Int J Clin Pract. 2006;60(9):1048-52.

13. Dogru T, Genc H, Tapan S,. Hyperuricemia in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(8):1042-3

14. Dogru T, Genc H, Ercin CN, Tapan S. Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2011;55(2):498-9.

15. Dogru T, Genc H, Kara M, Karadurmus N. Microalbuminuria and nonalcoholic fatty liver disease. Metabolism. 2010;59(9):E5

16. Dogru T, Karadurmus N, Tapan S, Genc H. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(7-8):1000-1.

17. Genc H, Karadurmus N, Kisa U ve ark. T. Transforming growth factor β (TGF-β) levels in otherwise healthy subjects with impaired glucose tolerance. Endokrynol Pol. 2010;61(6):691-4.

18. Dogru T, Sonmez A, Tasci I, Genc H. Symptomatic hypocalcemia due to oral risedronate therapy. Ind. J. Med. Sci 2005;59:542-543

19. Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, Tapan S, Karslioglu Y, Montalto G, Banach M, Toth P, Rizzo M. Low- and high-density lipoprotein subclasses in subjects with non-alcoholic fatty liver disease. J Clin Lipidol. 2015 Jul-Aug;9(4):576-582.

20. Celebi G, Genc H, Gurel H, ve ark. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol. 2015 May-Jun;21(3):139-45.

21. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, ve ark. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014

22. Kara M, Genc H, Tapan S, ve ark. Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2013 Jun;17(11):1536-41.

23. Gurel H, Genc H, Celebi G ve ark. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4305-4312.

1. Dogru T, Genc H, Ercin CN. Carotid atherosclerosis or nonalcoholic fatty liver disease: which comes first? Atherosclerosis. 2013 Dec;231(2):187-8.

2. Dogru T, Genc H,. C reactive protein levels in non-alcoholic fatty liver disease. J Hepatol. 2012 Feb;56(2):507-8

3. Dogru T, Genc H, Tapan S, Hyperuricemia in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(8):1042-3

4. Dogru T, Genc H, Ercin CN, Tapan S. Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2011;55(2):498-9.

5. Dogru T, Genc H, Kara M, Karadurmus N. Microalbuminuria and nonalcoholic fatty liver disease. Metabolism. 2010;59(9):5

6. Dogru T, Karadurmus N, Tapan S, Genc H. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(7-8):1000-1.

1. Genc H, Dogru T, Celebi G ve ark. Non-alcoholic fatty liver disease per se is not associated with carotid atherosclerosis.Gulhane Medical Journal, 2013; 55(2):84-88.

2. Kara M, Genc H. Comparison of the asymmetric dimethyl arginin levels and carotid intima media thickness with hemoglobin levels in patients with non-alcholic fatty liver disease Gulhane Medical Journal, 2012; 54(1):40-48.

1. Tapan S, Dogru T, Tasci I, Sonmez A, Erdem G, Genc H, ve ark. Decreased plasma apelin is positively correlated with adiponectin in patients with treatment naive type 2 DM. 15th Meeting of Balkan Clinical Laboratory Federation, Balkan Journal of Clinical Laboratory 2007;XIV,07,1:Abs.OP-14.

2. aCintosun U, Dogru T, H Genc, ve ark. TWEAK; a novel player in the pathogenesis of hepatic fibrosis in non alcoholic fatty liver disease? 24th Conference of the Asian Pacific Associaton for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S365.

3. Ercin CN, Dogru T, Genc H, ve ark. A. Insulin resıstance but not visceral adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease. 24th Conference of the Asian Pacific Associaton for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S369.

4. Genc H, Dogru T, Celebi G, ve ark. High plasma levels of pentraxin 3 is associated with endothelial dysfunction in non alcoholic fatty liver disease. 24th Conference of the Asian Pacific Associaton for the Study of the Liver (APASL), Istanbul. Hepatol Int (2015) 9 (Suppl 1): S376.

5. Hancerliogullari O, Meral UM, Genc H. Hyperbilirubinemia after Surgery: Postoperative Diagnosed Gilbert’s Disease.The 49th Congress of the European Society for Surgical Research May 21-24, 2014, Budapest, Hungary Eur Surg Res 2014;52:93-250.

6. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, ve ark. Plasma apelin and ADMA levels in patients with essential hypertension. 20 th European Meeting on Hypertension Oslo, Norway, 18-21 June 2010. Journal of Hypertension, Vol:28, e-Supplement A, June 2010, PP.12.451

7. Koc B., Sonmez A., Dogru T., Tasci I., Genc H., ve ark. Leptin levels in young, non-obese, male smokers and non-smokers. Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 417, Tu-P13:323, Elsevier, Ireland, 2006.

8. Dogru, T., Sonmez, A., Genc H ve ark. The effect of fibrinogen and platelet aggregation on cardiovascular risk in prediabetic subjects’’, Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 395, Tu-P11:226, Elsevier, Ireland, 2006

9. Dogru, T., Tasci, I., Sonmez, A., Genc, H., ve ark. “Soluble P-selectin levels in subjects with prediabetes’’, Atherosclerosis Supplements, XIV. International Symposium on Atherosclerosis, Rome, vol. 7, 206, Tu-P7:96, Elsevier, Ireland, 2006.

10. I Tasci, T. Dogru, A.Sonmez, H. Genc, ve ark. Soluble CD40 Ligand levels in otherwise healthy subjects with impaired fasting glucose. 2nd International Congress on Prediabetes and The Metabolic Syndrome, Barcelona, Diabetes & Vascular Disease Research, 2007:4(Supplement 1); S106 a

11. Ercin CN, Dogru T, Genc H, ve ark. Insulin Resistance But Not Visceral Adiposity Index Is Associated With Liver Fibrosis In Nondiabetic Subjects With Nonalcoholic Fatty Liver Disease. 14th International Euroasian Congress of Gastroenterology and Surgery.Euroasian Journal of Hepato- Gastroenterology. 2014 July-December volüme 3 issue 2

12. Genc H, Meral UM, Hançerlioğlu O, Alper E.Esophageal obstruction after mixture of grain meal. 14th International Euroasian Congress of Gastroenterology and Surgery.Euroasian Journal of Hepato- Gastroenterology. 2014 July-December volüme 3 issue 2

13. Haymana C, Sonmez A, Tapan S, Safer U, Çelebi G, Öztürk Ö, Genc H ve ark. Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus. 12th Europan Congress of Endocrinology 24-28 April, Prague, Czech Republic

14. S. Tapan ,A Sonmez , T Dogru , H.Genc, ve ark. ISKEMIA-MODIFIED ALBUMIN CAN BE A MARKER FOR DIABETES MELLITUS BUT NOT FOR IMPAIRED GLUKOSE TOLERANCE.The 3nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy),May 13-16. 2010

15. Sonmez A, Genc H, Celebi G, ve ark. The relationship between the hemoglobin levels and the cardiovascular risk factors in prediabetes. 3rd International Congress on Prediabetes and the Metabolic Syndrome, Nice, Fransa, A140, 1-4 Nisan 2009.

16. Erdem G, Genc H, Tapan S, ve ark. The leukocyte and platelet indices in patients with impaired glucose tolerance, The 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), İspanya, s36A, 30 Ekim-2 Kasım 2008.

17. Erdem G, Genc H, Tapan S, ve ark.. Circulating von Willebrand factor levels in patients with prediabetes. The 2nd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), İspanya, 30 Ekim-2 Kasım 2008, s35A.

1. Sönmez A, Genç H, Çelebi G, ve ark. Prediyabet olgularında hemoglobin düzeyleri ile kardiyovasküler risk faktörleri arasında ilişki var mı? 45. Ulusal Diyabet Kongresi, 20-24 Mayıs 2009, Antalya, Türkiye. Program ve Özet Kitabı, SS06, 2009.

2. Taşçı İ, Erdem G, Özgür G, Tapan S, Dogru T, Genç H, ve ark. İzole hiperkolesterolemili olgularda LDL-kolesterol düşüşü sağlanması plazma apelin düzeyini yükseltir. 10. Ulusal İç Hastalıkları Kongresi, Antalya, 2008:S10.

3. Aslan F, Genc H, Celebi G, ve ark. Ozefagus varis kanamasi nedeniyle endoskopik band ligasyonu yapilan hasta kalp krizi gecirirse ne yaparsiniz? P189. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya

4. Genc H, Dogru T, Ercin CN, ve ark. Alkolik olmayan yagli karaciger hastaliginda dolasimda bulunan beyaz kure hucre sayisi artmaktadir. P174. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

5. Genc H, Dogru T, Ercin CN, ve ark. Alkolik olmayan yagli karaciger hastaliginda urik asit duzeyleri ve histopatolojik bulgular ile iliskisi. P171. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

6. Dogru T, Genc H, Tapan S, ve ark. Alkolik olmayan yagli karaciger hastaligindaki kardiyovaskuler risk artisinda fetuin-a’nin rolu. P169. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya

7. Aslan F, Genc H, Sakin YS, ve ark. Dermatomyozit Crohn hastaligi birlikteligi: olgu sunumu. P112. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya

8. SakinYS, Polat Z, YildizB, Genc H, ve ark. AKUT KOLESTAZ TABLOSU İLE PREZENTE OLAN AKUT HEPATİT A,B VE D KOENFEKSİYONU (ÜÇLÜ AKUT HEPATİT) SAPTANAN HASTA: VAKA SUNUMU P163. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

9. Sakin YS, Polat Z, Aslan F, Tüzün A, Genç H, ve ark. KOROZİV ÖZEFAJİT-DUODENİT VE PİLOR STENOZU. ENDOSKOPİK TEDAVİ Mİ? CERRAHİ TEDAVİ Mİ? P30 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

10. Polat Z, Küçükyıldırım S, Erdem B, Uygun A, Kantarcıoğlu M, Genç H ve ark. Gastrointestinal Kanserli hastaların periferik kanında CK20 ve MUC1 mRNA Tayini. P333. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

11. Polat Z, Küçükyıldırım S, Kantarcıoğlu M, Erdem B, Gülşen M, Kilciler G, Çelebi G, Ergün H, Genç H, ve ark. Kolorektal kanserli hastalarda metastaz belirteci olarak periferal kandaki total RNA miktarının değerlendirilmesi P331 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya

12. Aslan F, Çelebi G, Sakin YS, Genç H ve ark. ÜST GASTROİNTESTİNAL KANAMANIN NADİR NEDENİ; İSKEMİK ÖZEFAJİT OLGU SUNUMU.P2 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya.

13. Aslan F, Çelebi G, Polat Z, Kantarcıoğlu M, Genç H ve ark. İLEOÇEKAL VALV AÇILIM ANOMALİSİ; Olgu Sunumu P285. 28. Ulusal Gastroenteroloji Haftasi, 16-20 Kasim 2011, Antalya

14. Karadurmus N, Dogru T, Genc H, ve ark. Immunsupresif tedavi uygulayan hekimlerin hepatit B enfeksiyonu taramasina yaklasimi. P 91. 27. Ulusal Gastroenteroloji Haftasi 24-28 Kasim 2010, Antalya.

15. Genc H, Dogru T, Tapan S, ve ark. Alkolik olmayan yagli karaciger hastaliginda glukoz tolerans anormalliklerinin arastirilmasi. P274. 27. Ulusal Gastroenteroloji Haftasi 24-28 Kasim 2010, Antalya.

16. Genc H, Dogru T, Kara M, ve ark. Metabolik sendrom bulunmayan alkolik olmayan yagli karaciger hastaliginda karotid ateroskleroz riski artmamaktadir. P275. 27. Ulusal Gastroenteroloji Haftasi 24-28 Kasim 2010, Antalya.

17. Kara M, Dogru T, Genc H, ve ark. Alkolik olmayan yagli karaciger hastaligi ve ateroskleroz iliskisinde hemoglobinin rolu. P 276. 27. Ulusal Gastroenteroloji Haftasi 24-28 Kasim 2010, Antalya.

18. Tasci I, Erdem G, Ozgur G, Genc H, ve ark.. HMG-CoA reductase inhibitor treatment and platelet indices in patients with hypercholesterolemia. 5. Ulusal Metabolik Sendrom Sempozyumu, Antalya, 9-13 Nisan 2008, Obesity Reviews;9:276 (No:17).

19. Dogru T, Tasci I, Sonmez A, Genc H, ve ark. Soluble P-selectin levels in subjects with prediabetes. European J Clin Invest, 2. Klinik Vasküler Biyoloji Kongresi, Antalya, vol. 36, 283, P50, Blackwell Publishing, 2006.

20. Dogru T, Sonmez A, Genc H, ve ark. The effect of fibrinogen and platelet aggregation on cardiovascular risk in prediabetic subjects. European J Clin Invest, 2. Klinik Vasküler Biyoloji Kongresi, Antalya, vol. 36, 283, P49, Blackwell Publishing, 2006.

21. Tasci I, Dogru T, Sonmez A, Genc H, ve ark. Soluble CD40 ligand levels are not altered in subjects with impaired fasting glucose. European J Clin Invest, 2. Klinik Vasküler Biyoloji Kongresi, Antalya, vol. 36, 272, P16, Blackwell Publishing, 2006

22. Ercin CN, Dogru T, Celebi G, Gürel H, Genc H, ve ark. Kan Üre Azotu Erken Dönem Alkolik Olmayan Karaciğer Yağlanması Olan Hastalarda Kardiyovasküler Risk için Bir Belirteç Değildir. 31. Ulusal Gastroenteroloji Haftası25-30 Kasım 2014.

23. Cintosun Ü, Dogru T, Genc H, ve ark. TWEAK ; Alkolik olmayan yagli karaciger hastaliginda fibrozis ile ilişkili yeni bir belirteç mi? 31. Ulusal Gastroenteroloji Haftası25-30 Kasım 2014.

24. Genc H, Dogru T, Celebi G, ve ark. Alkolik olmayan yagli karaciger hastaliginda yüksek plazma pentraksin-3 düzeyi endotel disfonksiyonu ile ilişkilidir. 31. Ulusal Gastroenteroloji Haftası25-30 Kasım 2014.

25. Genc H, Dogru T, Tapan S, ve ark. Alkolik olmayan yagli karaciger hastaliginda plazma vaspin duzeyleri ile insulin direnci, adiponektin ve histolojik bulgular arasindaki iliskinin arastirilmasi. P078. 8. Ulusal Hepatoloji Kongresi, 1-5 Haziran 2011, Ankara.

26. Genc H, Dogru T, ve ark. Alkolik olmayan yagli karaciger hastaliginda karotid ateroskleroz riski: gercekten yuksek mi? P080 8. Ulusal Hepatoloji Kongresi, 1-5 Haziran 2011, Ankara.

27. Erdem G, Genc H, Tasci I ve ark. Glukoz tolerans bozukluğu bulunan bireylerde plazma fibrinojen düzeylerinin araştırılması, 44. Ulusal Diyabet Kongresi, PS37, Antalya, 2008.

28. Genc H, Tasci I, Erdem G, ve ark. Glukoz tolerans bozukluğu bulunan hastalarda trombosit göstergeleri, 44. Ulusal Diyabet Kongresi, PS46, Antalya, 2008.

29. Erdem G, Genc H, Tasci I ve ark.. Glukoz tolerans bozukluğu bulunan hastalarda lipid profilleri. 44. Ulusal Diyabet Kongresi, Antalya, PS44, 2008.

30. Genc H, Tapan S, Erdem G, ve ark.. Glukoz tolerans bozukluğu bulunan hastalarda kan beyaz küre düzeylerinin değerlendirilmesi. 44. Ulusal Diyabet Kongresi, Antalya, PS29, 2008.

31. Karadurmuş, N., Doğru, T., Sönmez, A., Pınar, M., Genç, H ve ark. Diyabetik hastalarda aspirin kullanımı. 41. Ulusal Diyabet Kongresi, P26, Antalya, 2005.

32. Yılmaz, S., Karadurmuş, N., Sönmez, A., Doğru, T., Pınar, M., Genç, H., ve ark. Diyabetik olgularda hipoglisemi ve ilişkili faktörler. 41. Ulusal Diyabet Kongresi P58 Antalya, 2005

33. Genç, H., Sönmez, A., Doğru, T ve ark. Diyabetik hastalarda influenza ve pnömokok aşılarının kullanımı. 41. Ulusal Diyabet Kongresi, P57, Antalya, 2005.

34. Genç, H., Doğru, T., Sönmez, A., ve ark.. “Oral Risedronate kullanımına bağlı gelişen ağır ve semptomatik hipokalsemi”, 6. Ulusal İç Hastalıkları Kongresi, P-066, Antalya, 2004.